GW Pharmaceuticals to Present at Upcoming Investor Conferences
September 05 2017 - 12:09PM
- Morgan Stanley 15th Annual
Global Healthcare Conference on 13 September
- -
Leerink Partners Rare Disease & Immuno-Oncology Roundtable
Series on 27 September -
GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a
biopharmaceutical company focused on discovering, developing and
commercializing novel therapeutics from its proprietary cannabinoid
product platform, today announced that GW executive management will
be presenting at the Morgan Stanley 15th Annual
Global Healthcare Conference on Wednesday, 13 September 2017
at 11:05 a.m. EDT at the Grand Hyatt Hotel in New York City and the
Leerink Partners Rare Disease & Immuno-Oncology Roundtable
Series on Wednesday, 27 September 2017 at 2:30 p.m. EDT at the
Lotte New York Palace in New York City.
A live audio webcast of the presentations will
be available through GW’s corporate website at www.gwpharm.com on
the Investors section under Events & Presentations. A replay
will be available soon after the live presentation.
About GW Pharmaceuticals
plc
Founded in 1998, GW is a biopharmaceutical
company focused on discovering, developing and commercializing
novel therapeutics from its proprietary cannabinoid product
platform in a broad range of disease areas. GW is advancing an
orphan drug program in the field of childhood epilepsy with a focus
on Epidiolex (cannabidiol), for which GW has commenced a rolling
NDA submission with the FDA for the treatment of Dravet syndrome
and Lennox-Gastaut syndrome. The Company continues to evaluate
Epidiolex in additional epilepsy conditions and currently has
ongoing Phase 3 clinical trials in Tuberous Sclerosis Complex and
Infantile Spasms. GW commercialized the world’s first plant-derived
cannabinoid prescription drug, Sativex®, which is approved for the
treatment of spasticity due to multiple sclerosis in 30 countries
outside the United States. The Company has a deep pipeline of
additional cannabinoid product candidates which includes compounds
in Phase 1 and 2 trials for glioma, schizophrenia and epilepsy. For
further information, please visit www.gwpharm.com.
Enquiries:
GW Pharmaceuticals plc
Stephen Schultz, VP Investor Relations (U.S.) 917 280 2424 / 401 500 6570
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Sep 2023 to Sep 2024